RxDoctor Payments Data

Ryan King

Family Medicine · Goldsboro, NCNPI 1023753407

Payments from drug & device makers

$905in general payments, 2019–2025

Across 50 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • AbbVie$224
  • Lilly USA, LLC$92
  • Exact Sciences$75
  • Amgen$75
  • AstraZeneca$69
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$248
AbbVie13$224
Lilly USA, LLC5$92
Exact Sciences4$75
Amgen5$75
AstraZeneca4$69
GSK2$43
Medtronic1$26
Abbott1$20
Merck1$18
Eisai Inc.1$17

How this compares

$905 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$51,088
Medicare patients
156
Services billed
1,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$65,520
OzempicSemaglutide35$44,895
RybelsusSemaglutide33$42,221
EliquisApixaban44$35,533
JardianceEmpagliflozin39$34,713
JanuviaSitagliptin Phosphate13$21,624
LinzessLinaclotide24$18,100
WegovySemaglutide12$17,148
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,091
Repatha SureclickEvolocumab14$9,872
FarxigaDapagliflozin Propanediol11$9,645
SymbicortBudesonide/Formoterol Fumarate32$7,650
Breo ElliptaFluticasone/Vilanterol18$6,418
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,624
Spiriva HandihalerTiotropium Bromide11$5,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$248$104,26480 claims
Lilly USA, LLCMounjaro$92$65,52061 claims
GSKTrelegy Ellipta, Breo Ellipta$43$23,50945 claims
MerckJanuvia$18$21,62413 claims
AbbVieLinzess$224$18,10024 claims
AstraZenecaFarxiga, Symbicort$69$17,29643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →